Explore the vast range of titles available.

\"This book is a one-stop shop, easy-to-understand guidebook for cancer patients - This book explains important concepts about cancer such as the onset of cancer, surgery, radiotherapy, chemotherapy, recovering from cancer, the recurrence of cancer, rehabilitation programs, and pathways to the end of life - Provides information for patients to understand why, how, and what with each step of treatment plan, as well as a realistic range of possible outcome. This helps to reduce anxiety and give patients a greater sense of ownership in their treatment process\"-- Provided by publisher.

The roles of adipokines, proinflammatory cytokines, and adipose tissue macrophages in obesity-associated insulin resistance have been explored in both animal and human studies. However, our current understanding of obesity-associated insulin resistance relies on studies of artificial metabolic extremes. The purpose of this study was to explore the roles of adipokines, proinflammatory cytokines, and adipose tissue macrophages in human patients with modest obesity and early metabolic dysfunction. We obtained omental adipose tissue and fasting blood samples from 51 females undergoing gynecologic surgery. We investigated serum concentrations of proinflammatory cytokines and adipokines as well as the mRNA expression of proinflammatory and macrophage phenotype markers in visceral adipose tissue using ELISA and quantitative RT-PCR. We measured adipose tissue inflammation and macrophage infiltration using immunohistochemical analysis. Serum levels of adiponectin and leptin were significantly correlated with HOMA-IR and body mass index. The levels of expression of MCP-1 and TNF-α in visceral adipose tissue were also higher in the obese group (body mass index ≥ 25). The expression of mRNA MCP-1 in visceral adipose tissue was positively correlated with body mass index (r = 0.428, p = 0.037) but not with HOMA-IR, whereas TNF-α in visceral adipose tissue was correlated with HOMA-IR (r = 0.462, p = 0.035) but not with body mass index. There was no obvious change in macrophage phenotype or macrophage infiltration in patients with modest obesity or early metabolic dysfunction. Expression of mRNA CD163/CD68 was significantly related to mitochondrial-associated genes and serum inflammatory cytokine levels of resistin and leptin. These results suggest that changes in the production of inflammatory biomolecules precede increased immune cell infiltration and induction of a macrophage phenotype switch in visceral adipose tissue. Furthermore, serum resistin and leptin have specific roles in the regulation of adipose tissue macrophages in patients with modest obesity or early metabolic dysfunction.

\"Min Jin Lee introduces the indelible Casey Han: a strong-willed, Queens-bred daughter of Korean immigrants who is addicted to a glamorous Manhattan lifestyle she cannot afford. Fresh out of Princeton with an economics degree, no job, and a popular white boyfriend, Casey is determined to carve a space for herself in the glittering world she craves--but at what cost?\"--Back cover.

High-grade serous ovarian carcinoma is characterised by TP53 mutations, DNA repair defects, and genomic instability. We hypothesised that prexasertib (LY2606368), a cell cycle checkpoint kinase 1 and 2 inhibitor, would be active in BRCA wild-type disease. In an open-label, single-centre, two-stage, proof-of-concept phase 2 study, we enrolled women aged 18 years or older with measurable, recurrent high-grade serous or high-grade endometrioid ovarian carcinoma. All patients had a negative family history of hereditary breast and ovarian cancer or known BRCA wild-type status, measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status score 0–2, and adequate haematological, renal, hepatic, and bone-marrow function. Patients received intravenous prexasertib 105 mg/m2 administered over 1 h every 14 days in 28-day cycles until disease progression, unacceptable toxicity, or withdrawal of consent. The primary endpoint of investigator-assessed tumour response, based on RECIST version 1.1, was assessed per protocol (assessable patients who had undergone CT imaging at baseline and attended at least one protocol-specified follow-up) and by intention to treat. The final analysis of this cohort of patients with BRCA wild-type high-grade serous ovarian carcinoma is reported here. This ongoing trial is registered with ClinicalTrials.gov, number NCT02203513, and continues to enrol patients for the BRCA-mutated ovarian cancer cohort. Between Jan 20, 2015, and Nov 2, 2016, we enrolled 28 women with a median age of 64 years (IQR 58·0–69·5) who had previously received a median of 5·0 (IQR 2·5–5·0) systemic therapies. Most patients (22 [79%]) had platinum-resistant or platinum-refractory disease. All women received at least one dose of prexasertib, but four (14%) of 28 patients were not assessable for RECIST response. Eight (33%, 95% CI 16–55) of 24 patients assessable per protocol had partial responses. In the intention-to-treat population, eight (29%, 95% CI 13–49) of 28 had a partial responses. The most common (in >10% patients) grade 3 or 4 treatment-emergent adverse events were neutropenia in 26 (93%) of 28 patients, reduced white blood cell count in 23 (82%), thrombocytopenia in seven (25%), and anaemia in three (11%). Grade 4 neutropenia was reported in 22 (79%) patients after the first dose of prexasertib and was transient (median duration 6 days [IQR 4–8]) and recovered without growth-factor support in all cases. The treatment-related serious adverse event of grade 3 febrile neutropenia was reported in two (7%) patients. One patient died during the study due to tumour progression. Prexasertib showed clinical activity and was tolerable in patients with BRCA wild-type high-grade serous ovarian carcinoma. This drug warrants further development in this setting, especially for patients with platinum-resistant or platinum-refractory disease. Intramural Research Program of the National Institutes of Health and National Cancer Institute.

\"Throughout the world, oppressive regimes are being uprooted and replaced by budding democracies, but one exception remains: The People's Republic of North Korea. The Kim family has clung to power for three generations by silencing dissidents, ruling with an iron fist, and holding its neighbors hostage with threats of war. Under the leadership of Kim Jong Un, North Korea has come closer than ever to creating a viable nuclear arsenal, but widespread famine and growing resistance are weaking his regime's stability. In [this book], ... Chung Min Lee tells the story of the rise of the Kim Dynasty and its atrocities, motivations, and diplomatic goals\"--Provided by publisher.

ObjectivesPhysical inactivity is a risk factor for premature mortality and several non-communicable diseases. The purpose of this study was to estimate the global burden associated with physical inactivity, and to examine differences by country income and region.MethodsPopulation-level, prevalence-based population attributable risks (PAR) were calculated for 168 countries to estimate how much disease could be averted if physical inactivity were eliminated. We calculated PARs (percentage of cases attributable to inactivity) for all-cause mortality, cardiovascular disease mortality and non-communicable diseases including coronary heart disease, stroke, hypertension, type 2 diabetes, dementia, depression and cancers of the bladder, breast, colon, endometrium, oesophagus, stomach and kidney.ResultsGlobally, 7.2% and 7.6% of all-cause and cardiovascular disease deaths, respectively, are attributable to physical inactivity. The proportions of non-communicable diseases attributable to physical inactivity range from 1.6% for hypertension to 8.1% for dementia. There was an increasing gradient across income groups; PARs were more than double in high-income compared with low-income countries. However, 69% of total deaths and 74% of cardiovascular disease deaths associated with physical inactivity are occurring in middle-income countries, given their population size. Regional differences were also observed, with the PARs occurring in Latin America/Caribbean and high-income Western and Asia-Pacific countries, and the lowest burden occurring in Oceania and East/Southeast Asia.ConclusionThe global burden associated with physical inactivity is substantial. The relative burden is greatest in high-income countries; however, the greatest number of people (absolute burden) affected by physical inactivity are living in middle-income countries given the size of their populations.

\"PACHINKO follows one Korean family through the generations, beginning in early 1900s Korea with Sunja, the prized daughter of a poor yet proud family, whose unplanned pregnancy threatens to shame them all. Deserted by her lover, Sunja is saved when a young tubercular minister offers to marry and bring her to Japan. So begins a sweeping saga of an exceptional family in exile from its homeland and caught in the indifferent arc of history. Through desperate struggles and hard-won triumphs, its members are bound together by deep roots as they face enduring questions of faith, family, and identity\"-- Provided by publisher.

Landslides are one of the most important geohazards. In 2004–2016, more than 55,000 people lost their lives to landslides and this does not include deaths caused by seismically triggered landslides. Overall losses were estimated to be at USD 20 billion annually. The lives of many could be saved if more had been known regarding forecasting and mitigation. Studies have shown an increasing trend in landslides occurrence and fatalities. Over recent years, landslide risk assessment has been carried out extensively by geo-scientists worldwide. This review concentrates on the societal risks posed by landslides in various countries and the risk criteria used by various parts of the world in assessing landslide risks. The landslide risk tolerance criteria are strongly governed by utilitarian concerns i.e. financial power and the need for development. In developing countries, surprisingly high levels of tolerance are proposed for landslides. The risk criteria of Hong Kong and that of the Australian Geomechanics Society are widely employed in many countries. Although various risk tolerance levels have been proposed by various nations, many of them are still not being applied in their real-life scenarios. The procedures for setting risk criteria call for a wide agreement between geo-scientists, government decision makers, and the community. Risk criteria should be developed locally with historical landslide inventory, public perception, and engineering aspects being considered.

\"Maps are rarely given the same attention as other print media or art forms in urban history. Author Min Kyung Lee shows their rich potential in this lavishly illustrated study, which brings together maps and other archival materials along with drawings and paintings. She works across disciplines to examine mapping practices in the development of nineteenth-century Paris and the transformative role that urban mapping had on the city's modernization. Lee investigates Paris's formation as a modern city, ultimately framing the practice of cartography as a catalyst for the emergence of new spatial and compositional theories.\" -- Provided by publisher.

Background Checkpoint inhibitors have not been effective for prostate cancer as single agents. Durvalumab is a human IgG1-K monoclonal antibody that targets programmed death ligand 1 and is approved by the U.S. Food and Drug Administration for locally advanced or metastatic urothelial cancer and locally advanced, unresectable stage 3 non-small cell lung cancer. Olaparib, a poly (ADP-ribose) polymerase inhibitor, has demonstrated an improvement in median progression-free survival (PFS) in select patients with metastatic castration-resistant prostate cancer (mCRPC). Data from other trials suggest there may be improved activity in men with DNA damage repair (DDR) mutations treated with checkpoint inhibitors. This trial evaluated durvalumab and olaparib in patients with mCRPC with and without somatic or germline DDR mutations. Methods Eligible patients had received prior enzalutamide and/or abiraterone. Patients received durvalumab 1500 mg i.v. every 28 days and olaparib 300 mg tablets p.o. every 12 h until disease progression or unacceptable toxicity. All patients had biopsies of metastatic lesions with an evaluation for both germline and somatic mutations. Results Seventeen patients received durvalumab and olaparib. Nausea was the only nonhematologic grade 3 or 4 toxicity occurring in > 1 patient (2/17). No patients were taken off trial for toxicity. Median radiographic progression-free survival (rPFS) for all patients is 16.1 months (95% CI: 4.5–16.1 months) with a 12-month rPFS of 51.5% (95% CI: 25.7–72.3%). Activity is seen in patients with alterations in DDR genes, with a median rPFS of 16.1 months (95% CI: 7.8–18.1 months). Nine of 17 (53%) patients had a radiographic and/or PSA response. Patients with fewer peripheral myeloid-derived suppressor cells and with alterations in DDR genes were more likely to respond. Early changes in circulating tumor cell counts and in both innate and adaptive immune characteristics were associated with response. Conclusions Durvalumab plus olaparib has acceptable toxicity, and the combination demonstrates efficacy, particularly in men with DDR abnormalities. Trial registration ClinicalTrials.gov identifier: NCT02484404 .